Understanding the microbiology of the Aspergillus cell wall and the efficacy of caspofungin

References

• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445–1457
   PubMed Web of Science ®Google Scholar
• Morrison VA. Caspofungin: an overview. Expert Rev Anti Infect Ther 2005; 3: 697–705
   PubMedGoogle Scholar
• Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215–222
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42: 1171–1178
   PubMed Web of Science ®Google Scholar
• Zaas AK, Steinbach WJ. Micafungin: the US perspective. Expert Rev Anti Infect Ther 2005; 3: 183–190
   PubMedGoogle Scholar
• Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310–350
   PubMed Web of Science ®Google Scholar
• Beauvais A, Bruneau JM, Mol PC, et al. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001; 183: 2273–2279
   PubMed Web of Science ®Google Scholar
• Mouyna I, Henry C, Doering TL, Latge JP. Gene silencing with RNA interference in the human pathogenic fungus Aspergillus fumigatus. FEMS Microbiol Lett 2004; 237: 317–324
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480–1489
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001–3012
   PubMed Web of Science ®Google Scholar
• Bowman JC, Abruzzo GK, Flattery AM, , et al. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother in Press.
   Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–2568
   PubMed Web of Science ®Google Scholar
• Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474–3481
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867–4875
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Spreghini E, Santinelli A, et al. Efficacy of caspofungin against Aspergillus terreus. Antimicrob Agents Chemother 2005; 49: 5133–5135
   PubMed Web of Science ®Google Scholar
• Sivak O, Bartlett K, Risovic V, et al. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J Pharm Sci 2004; 93: 1382–1389
   PubMed Web of Science ®Google Scholar
• van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 732–740
   PubMed Web of Science ®Google Scholar
• Singh G, Imai J, Clemons KV, Stevens DA. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother 2005; 49: 1369–1376
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464–1471
   PubMed Web of Science ®Google Scholar
• Hickey E, Abruzzo G, Bowman JC, et al. Caspofungin versus Amphotericin B treatment of Aspergillus fumigatus in kidneys of chronically immunosuppressed infected mice. Therapy 2005; 4: 615–621
   Google Scholar
• Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003; 47: 1995–1998
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950–2956
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251–255
   PubMed Web of Science ®Google Scholar
• Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44: 2310–2318
   PubMed Web of Science ®Google Scholar
• Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058–5068
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Huang H, Cheng S, Derendorf H, Nguyen MH. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother 2006; 50: 2569–2572
   PubMed Web of Science ®Google Scholar
• Chiller T, Farrokhshad K, Brummer E, Stevens DA. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001; 39: 99–103
   PubMed Web of Science ®Google Scholar
• Hohl TM, Van Epps HL, Rivera A, et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog 2005; 1: e30
   PubMed Web of Science ®Google Scholar
• Steele C, Rapaka RR, Metz A, et al. The beta-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus. PLoS Pathog 2005; 1: e42
   PubMed Web of Science ®Google Scholar
• Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2: e35
   PubMed Web of Science ®Google Scholar
• Kahn JN, Hsu MJ, Racine F, Giacobbe R, Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50: 2214–2216
   PubMed Web of Science ®Google Scholar
• Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106: 466–473
   PubMed Web of Science ®Google Scholar
• Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005; 50: 196–205
   PubMed Web of Science ®Google Scholar